Discover how you can maximize hit recovery and rapidly down-select blocking antibodies from plasma B cells in a single day.
Explore case studies for the rapid discovery of antibodies against challenging targets.
Philip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.
Learn how we enable lead candidate down-selection in 1 day by performing functional characterization during primary screening. Case studies highlight how our customers are dramatically accelerating development of next-generation antibody therapeutics.